


03c0
#9
1/21/03
83/

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
A0000425-01-CFP

In Re Application Of: **RICHARD DENNIS DYER, ET AL**



Serial No. 10/071,032 ✓	Filing Date February 8, 2002 ✓	Examiner Unknown	Group Art Unit Unknown
----------------------------	-----------------------------------	---------------------	---------------------------

Title: **BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS**

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR


the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
A0000425-01-CFP

In Re Application: RICHARD DENNIS DYER, ET AL



Serial No.

10/071,032

Filing Date

February 8, 2002

Examiner

Unknown

Group Art Unit

Unknown

BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 23-0455 as described below. A duplicate copy of this sheet is enclosed.

- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited May 31, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Nancy Dernbach

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: May 31, 2002

Claude F. Purchase, Jr.

Registration No. 47,871

Warner-Lambert Company

Patent Department

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-1692

Fax (734) 622-1553


cc:

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

9



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFR

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
		WO	95/35296	Takatani, et al	12/28/1995	
		WO	01/63244 A1	Chen, et al	08/30/2001	
		EP	0 404 525 B1	Naka, et al	05/15/1996	
		GB	2 097 396 A	Seivaku. et al	11/03/1982	
		DE	41 37 437 A1	Furrer, et al	05/19/1993	
		EP	0 404 525 A	Naka. et al	12/27/1990	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/071032
Filing Date	February 8, 2002
First Named Inventor	Richard Dennis Dyer, et.al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	A0000425-01-CFP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361	
		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	
		CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
		DERWENT ABSTRACT, 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhesion molecule expression (Eng.)"	
		DERWENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating anteriosclerosis"	
		DERWENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto:immune diseases, etc."	
		DERWENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs. - are orally administered antitumour agents without side effects of parent"	
		KAUL, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900	
		KAUL, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Aclaracil (1-allyl-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498	
		KAUL, Von R., et al, "Identifizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", Arzneim.-Forsch./Drug Res., 1982; 32(I)(6); pp 610-612	
		BROWN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1972; pp 2385-2391	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/071032
				Filing Date	February 8, 2002
				First Named Inventor	Richard Dennis Dyer, et al
				Group Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	A0000425-01-CFP
Sheet	3	of	3		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PECORARI, Piergiogio, et al, "Synthesis And Biological Activity of Pyrimido [2,1-b] [1,3]Thiazine, [1,3]Thiazino[3,2-a]Purine And [1,2,3]Triazolo[4,5-d][1,3]Thiazino[3,2-a]Pyrimidine Derivatives And Thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
		DE MELO, S. J., et al, "5-fluoro (3H) pyrimidine-4-ones: synthese, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques francaises, 1992, 50, n 1, pp 39-51	
		Chem. Abstr. 1992; 117; pp 143023e - COPY TO FOLLOW	
		FASKHUTDINOW, et al, Kim. Farm. Zh. 1988; 22(5); pp 557 - COPY TO FOLLOW	
		Chem. Abstr. 1988; 109; pp 162901r - COPY TO FOLLOW	
		TOZKOPARAN, Birsen, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331, (Weinheim, Germany); 1998; pp 201-206	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.